New England Journal of Medicine Publishes DBV Technologies’ Phase 3 EPITOPE Trial Data Evaluating Viaskin Peanut in Toddlers

(24/7 MARKET NEWS) – DBV Technologies (NASDAQ:DBVT) STATED, yesterday evening, that its Phase 3 EPITOPE trial of epicutaneous immunotherapy (EPIT) with Viaskin Peanut in children 1 – 3 years was published in the New England Journal of Medicine, reinforcing the potential of a new food allergy treatment option for this community.

DBV Technologies is trading at $1.76, up $0.11 (+6.67%), on 127K premarket shares traded.

Its 52-week range is $1.08 to $3.43. If it can break through its next key inflection point of $1.80, on stronger volume, its setup is favorable for a potential very large run.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.